The global human microbiome therapeutics market is estimated to grow at a CAGR of 60.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1bn in 2024.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 106 tables and 47 figures– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Download Free Sample Pages of this report

Report Scope

Global Human Microbiome Therapeutics Market forecast from 2019-2029

Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Sector:

  • Gastrointestinal Disorders
  • Infectious Diseases
  • Metabolic Diseases
  • Dermatological Conditions
  • Other Disorders

Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Region:

  • U.S.
  • EU5: Germany, France, U.K., Italy, Spain
  • Japan
  • Rest of the World

The human microbiome market revenue forecast 2019-2029 for the US, EU5 and Japan markets are further broken down by sector.

This report discusses the top 20 companies in the human microbiome therapeutics market:

  • 4D Pharma
  • AOBiome Therapeutics
  • C3J Therapeutics
  • Caelus Health
  • Enterome Bioscience
  • Ferring Pharmaceuticals
  • Finch Therapeutics/Crestovo
  • IGEN BIOTECH GROUP
  • Immuron
  • Intrexon Corporation
  •  MaaT Pharma
  • MatriSys Biosystem
  • Microbiome Therapeutics LLC
  • Osel
  • Ritter Pharmaceuticals
  • Second Genome
  • Seres Therapeutics
  • Synlogic
  • Synthetic Biologics
  • Vedanta Biosciences

This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products

This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.

Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.

Key Questions Answered by this Report:

  • How is the market for human microbiome therapeutics evolving?
  • What is driving and restraining the human microbiome therapeutics market dynamics?
  • What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
  • How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2019 to 2029?
  • Which submarkets will be the main driver of growth in the overall market from 2019 to 2029?
  • How will the regional market shares in the human microbiome therapeutics market change by 2029 and which geographical region will lead the market in 2029?